Abstract
Alpha-particle therapy has received increased attention during the last few years because of the development of new targeting constructs and new labeling techniques and the availability of suitable α-particle – emitting radionuclides. This work provides an overview of methods that have been used in clinical trials in estimating the absorbed dose to tumors and healthy tissue in patients following such α-particle therapy. Similarities and differences compared to conventional therapies using β¯-particle emitters are presented. The specific challenges of establishing accurate dosimetry for α- particles in the individual patient are also discussed, as is the effect that improved patient-specific dosimetry might have on the overall efficacy of this type of therapy.
Keywords: Alpha-particles, clinical trials, dosimetry, radionuclide therapy, regulators, (MTA, PATIENT PHARMACOKINETICS, PATIENT DOSIMETRY, Gamma Counters and Probes, Quantitative Imaging
Current Radiopharmaceuticals
Title: Patient-Specific Alpha-Particle Dosimetry
Volume: 4 Issue: 4
Author(s): Stig Palm, Jorgen Elgqvist and Lars Jacobsson
Affiliation:
Keywords: Alpha-particles, clinical trials, dosimetry, radionuclide therapy, regulators, (MTA, PATIENT PHARMACOKINETICS, PATIENT DOSIMETRY, Gamma Counters and Probes, Quantitative Imaging
Abstract: Alpha-particle therapy has received increased attention during the last few years because of the development of new targeting constructs and new labeling techniques and the availability of suitable α-particle – emitting radionuclides. This work provides an overview of methods that have been used in clinical trials in estimating the absorbed dose to tumors and healthy tissue in patients following such α-particle therapy. Similarities and differences compared to conventional therapies using β¯-particle emitters are presented. The specific challenges of establishing accurate dosimetry for α- particles in the individual patient are also discussed, as is the effect that improved patient-specific dosimetry might have on the overall efficacy of this type of therapy.
Export Options
About this article
Cite this article as:
Palm Stig, Elgqvist Jorgen and Jacobsson Lars, Patient-Specific Alpha-Particle Dosimetry, Current Radiopharmaceuticals 2011; 4 (4) . https://dx.doi.org/10.2174/1874471011104040329
DOI https://dx.doi.org/10.2174/1874471011104040329 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Mass Spectrometric Imaging of the Nervous System
Current Pharmaceutical Design Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Celecoxib and Dimethylcelecoxib Block Oxidative Phosphorylation, Epithelial-Mesenchymal Transition and Invasiveness in Breast Cancer Stem Cells
Current Medicinal Chemistry Glutathione Peroxidase Activity of Ebselen and its Analogues: Some Insights into the Complex Chemical Mechanisms Underlying the Antioxidant Activity
Current Chemical Biology Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products
Current Medicinal Chemistry Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology Effect of O6-Substituted Guanine Analogs on O6-methylguanine DNA-methyltransferase Expression and Glioblastoma Cells Viability
Medicinal Chemistry Alpha-Particle Microdosimetry
Current Radiopharmaceuticals Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Pathophysiological Role of Mitochondrial Potassium Channels and their Modulation by Drugs
Current Medicinal Chemistry Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor
Current Topics in Medicinal Chemistry Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia
Current Pharmaceutical Design Anti-Tumor Activity of Non-Nucleosidic Reverse Transcriptase Inhibitors
Current Pharmaceutical Design Antidepressants and Neuroinflammation: Can Antidepressants Calm Glial Rage Down?
Mini-Reviews in Medicinal Chemistry Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Current Signal Transduction Therapy Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery